Anesthesia Pharmacology Chapter 4: Autonomic (ANS) Pharmacology: Introduction
Antatomical Site |
Predominant Autonomic Tone |
Arterioles |
Sympathetic-adrenergic |
Veins |
Sympathetic-adrenergic |
Heart |
Parasympathetic-cholinergic |
Ciliary Muscle |
Parasympathetic-cholinergic |
Gastrointestinal Tract |
Parasympathetic-cholinergic |
Salivary Glands |
Parasympathetic-cholinergic |
Sweat Glands |
Sympathetic-cholinergic |
Taylor, P. Agents Acting at the Neuromuscular Junction and Autonomic Ganglia In, Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) The McGraw-Hill Companies, Inc.,1996, pp.193-195. Adapted from Table 9-3 |
|
|
|
Cholinergic
Hemicholinium (HC-3) blocks the choline transport system into the nerve ending, thus limiting acetylcholine (ACh) synthesis.
Adrenergic
Α-methyltyrosine inhibits tyrosine hydroxylase thus preventing synthesis of norepinephrine.
|
Methyldopa inhibits aromatic amino acid decarboxylase and is itself decarboxylated and hydroxylated to form the "false transmitter" α-methyl norepinephrine.
|
Cholinergic
Botulinum toxin can be used clinically to treat ocular muscle spasms, muscle dystonias, and spasms.
Botulinus toxin binding at a presynaptic site blocks ACh release.
Vesamicol blocks ACh transport into storage vesicles, thus limiting release.
Adrenergic
Bretylium and guanethidine prevent action-potential mediated norepinephrine release.
Transient release may occur with these agents because they displace norepinephrine from storage sites.
Tyramine, amphetamine, and ephedrine can produce a brief liberation of transmitter.
Reserpine, by inhibiting vesicular uptake, produces a slow, depletion of norepinephrine, ultimately causing adrenergic blockade.
Cytoplasmic MAO metabolizes the neurotransmitter.
Reserpine similarly depletes dopamine and serotonin. Physiological effects of reserpine are due to depletion of many transmitters.
Cholinergic
Tetraethylammonium, trimethaphan and hexamethonium are nicotinic ganglionic antagonists.
Decamethonium, a depolarizing drug, selectively causes neuromuscular blockade.
All classes of muscarinic receptors are blocked by atropine.
Adrenergic
Phenylephrine (Neo-Synephrine): an α1 receptor agonist.
Clonidine (Catapres): an α2 receptor agonist.
Prazosin (Minipress): an example of an α1 receptor antagonist.
Yohimbine (Yocon): an example of an α2 receptor antagonist.
Isoproterenol (Isuprel): β1 and β2 receptor agonist.
Dobutamine (Dobutrex): a relatively selective myocardial β1 receptor agonist.
Terbutaline (Brethine): relatively selective β2 receptor agonist.
Propranolol (Inderal): an example of a non-selective beta-adrenergic receptor blocker.
Metoprolol (Lopressor): an example of a relatively selective β1 receptor antagonist.
Termination of Transmitter Effects: Site 4
Cholinergic
Acetylcholinesterase inhibitors prevent breakdown and inactivation of acetylcholine.
ACh accumulation at the neuromuscular junction causes flacid paralysis.
ACh accumulation at postganglionic muscarinic sites results in either excessive stimulation (contraction and secretion) or inhibition (hyperpolarization), depending on the site.
ACh accumulation at autonomic ganglia cause increased transmission.
Adrenergic
Interference with neurotransmitter reuptake results in potentiation of catecholamine effects.
Cocaine and imipramine are examples of drugs that inhibit the reuptake system.
Monoamine oxidase (MAO) inhibitors potentiate actions of tyramine; whereas catechol-O-methyl transferase (COMT) inhibitors (pyrogallol and tropolone) only slightly increase catecholamine effects.